Johnson & Johnson (JNJ) Economic Moat Analysis44

Moat44

Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.

structural advantage · 2/4 · TREMFYA has specific disclosed patent protection, while historical DARZALEX and ERLEADA share gains and current medicine growth corroborate commercial differentiation. This supports a bounded intangible-asset advantage. The catalog does not demonstrate broad relative superiority, a company-wide protection horizon or structural advantages across every business.

durability · 1/4 · TREMFYA's composition patent family has a projected U.S. expiry in 2031, providing a finite protection reference. STELARA's substantial current growth drag demonstrates realized franchise erosion. Replacement medicines are growing, but the passages do not establish that their protection and economics will sustain the advantage through successive patent cycles.

customer dependency · 2/4 · Historical medicine share gains and current growth from established medicines and contact lenses indirectly indicate sustained customer preference. These operating outcomes support some dependence on differentiated products. They do not establish contractual lock-in, quantified switching friction, patient persistence or dependence on a proprietary device ecosystem.

erosion resilience · 2/4 · Innovative Medicine achieved 7.9% third-quarter 2026 operational growth despite STELARA's approximately 690-basis-point drag, and MedTech also grew. This demonstrates some portfolio replacement capacity. Continued declines in several franchises and ongoing patent challenges limit confidence that resilience will persist across future exclusivity losses.

Pricing power—

Insufficient evidence for every rubric criterion; no category score is inferred.

realized pricing · — · The supplied passages report sales growth and product drivers without separating realized price from volume and mix. Medicare maximum fair prices and implementation establish constraints, but do not quantify Johnson & Johnson's realized pricing outcome. The earlier contact-lens price-action evidence is absent from this catalog.

retention · 2/4 · Established medicines' share gains and continued growth in medicines and contact lenses provide indirect evidence of sustained demand. This supports a mixed retention assessment without requiring subscription churn measures. Launches, market expansion and changing product mix prevent attribution to repeat purchasing alone, particularly given declining mature franchises.

margin resilience · 2/4 · For nine months in 2026, gross profit increased 6.7% as sales rose 7.4%, while gross margin slipped to 67.6% from 68.0%. This demonstrates partial resilience with some compression. Higher selling and research expense ratios further temper the assessment; these results do not isolate pricing power.

contractual freedom · 1/4 · CMS's announced maximum fair prices and commencement of program implementation demonstrate constrained price-setting freedom for selected drugs. This warrants a weak assessment rather than an unknown one. The disclosure leaves the total portfolio impact uncertain, and commercial contract terms are insufficient to establish broader pricing discretion.

Predictability93

5 consecutive published annual periods. Equal weights: nondeclining revenue frequency; revenue-growth volatility (5–40pp); positive FCF frequency; FCF-margin volatility (3–20pp). Stability indicator, not a growth forecast.

Nondeclining revenue years (%)

75.00

Revenue growth volatility (pp)

6.37

Positive FCF years (%)

100.00

FCF margin volatility (pp)

1.42

observedAnnualPeriods

5.00

Financial strength71

Equal-weight grades: debt/FCF (1–8x), net debt/earnings before interest and tax (0–5x), interest service (1–12x), current ratio (0.75–2x). Earnings use reported operating income, an original issuer-reported unadjusted EBIT reconciled to net income, income tax and signed net interest, or reported pretax profit plus reported gross interest expense. Reported EBIT is distinct from GAAP operating income and gross interest. Interest service uses earnings/interest expense; if unavailable, it uses reported operating cash flow/cash interest paid, without relabeling cash paid as accrued expense. Nonpositive cash flow/earnings score 0 for their service component; reported zero interest with a positive numerator scores 100. Net cash scores 100 for net leverage. Missing disclosures remain unavailable. General nonfinancial-company rubric, not a credit rating; exceptional and nonoperating gains are not normalized out. IFRS finance-cost and cash-flow classifications retain their reported scope.

debtFcfGrade

79.52

netDebtEbitGrade

83.17

interestCoverageGrade

100.00

currentRatioGrade

22.21

Debt / FCF (x)

2.43

Net debt / operating income (x)

0.84

Current ratio (x)

1.03

Capital allocation94

Three-year equal-weight indicators: pretax return on average invested capital (0–25%; equity + debt − cash, each year and its prior year), share-count growth (0–5%, lower better), share-based cost/revenue (2–20%, lower better), consolidated FCF/net income (0–1x). Return uses reported operating income, an original issuer-reported unadjusted EBIT reconciled to net income, income tax and signed net interest, or EBIT calculated from reported pretax profit plus reported gross interest expense; the issuer-reported EBIT is distinct from GAAP operating income and gross interest; exceptional/nonoperating gains are not normalized out. Share-based cost uses the reported cash-flow add-back or, if absent, separately reported recognized compensation expense; the latter never becomes an FCF adjustment. Nonpositive net income scores 0 for cash conversion; absent income/FCF stays unavailable. ROIC remains undefined for nonpositive invested capital; the explicit asset-return alternative does not change the ROIC chart. Missing financial inputs alone never trigger an alternative. Does not establish acquisition quality or buyback timing.

3-year pre-tax operating return (%)

24.70

3-year average dilution (%)

-2.82

3-year average SBC / revenue (%)

1.38

cashConversionGrade

76.01

Management56

Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.

capital discipline · 2/4 · The completed $1 billion cash Firefly acquisition, $2.58 billion Sail acquisition option and compensation-related repurchases show actual capital choices. Substantial disclosed settlement obligations constrain flexibility. Acquisition returns remain unproven, and management's expectation of sufficient funding is not demonstrated cash generation; the evidence supports a mixed assessment.

incentive alignment · 3/4 · Actual three-year performance awards combine adjusted operational EPS and relative shareholder return, with variable payouts and a completed 2023–2025 payout. Ownership requirements, disclosed compliance and anti-hedging restrictions reinforce alignment. Schmid remained within his threshold transition period; adjusted metrics and strategic payout discretion limit the strength of the conclusion.

execution · 2/4 · Current medicine growth despite STELARA erosion, together with MedTech growth, demonstrates some successful portfolio execution through indirect operating evidence. Historical share gains offer additional support. Margin compression and unproven acquired development platforms temper the assessment; compensation payouts and management's innovation claims do not independently demonstrate execution quality.

governance · 2/4 · Independent directors evaluate and set Chairman/CEO compensation, and shareholders have specified special-meeting rights. These are substantive safeguards. The combined Chairman/CEO role continued, with the independent-chair proposal rejected in April 2026. Strategic compensation discretion and limited evidence of oversight outcomes support a mixed assessment rather than exceptional governance.